Literature DB >> 23063736

Applications of the method of high resolution melting analysis for diagnosis of Leber's disease and the three primary mutation spectrum of LHON in the Han Chinese population.

Guanglin Cui1, Hu Ding, Yujun Xu, Bin Li, Dao Wen Wang.   

Abstract

Current screening methods, such as single strand conformational polymorphism (SSCP), denaturing high performance liquid chromatography (dHPLC) and direct DNA sequencing that are used for detecting mutation in Leber's hereditary optic neuropathy (LHON) subjects are time consuming and costly. Here we tested high-resolution melt (HRM) analysis for mtDNA primary mutations in LHON patients. In this study, we applied the high resolution melting (HRM) technology to screen mtDNA primary mutations in 50 LHON patients from their peripheral blood. In order to evaluate the reliability of this technique, we compared the results obtained by HRM and direct mtDNA sequencing. We also investigated the spectrum of three most common mtDNA mutations implicated in LHON in the Han Chinese population. The results showed HRM analysis differentiated all of the mtDNA primary mutations and identified 4 additional mtDNA mutations from 50 patients in the blind study. The prevalence of three primary mutations were 11778G>A (87.9%), 14484T>C (6.5%) and 3460G>A (1.7%) in the Han Chinese population. In conclusion, HRM analysis is a rapid, reliable, and low-cost tool for detecting mtDNA primary mutations and has practical applications in molecular genetics.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23063736     DOI: 10.1016/j.gene.2012.09.110

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  8 in total

1.  Enhanced primer selection and synthetic amplicon templates optimize high-resolution melting analysis of single-nucleotide polymorphisms in a large population.

Authors:  Carol M Bruzzone; Patrick S Tawadros; Lisa A Boardman; Clifford J Steer
Journal:  Genet Test Mol Biomarkers       Date:  2013-06-22

2.  A Meta-analysis of the association between different genotypes (G11778A, T14484C and G3460A) of Leber hereditary optic neuropathy and visual prognosis.

Authors:  Dong-Yu Guo; Xia-Wei Wang; Nan Hong; Yang-Shun Gu
Journal:  Int J Ophthalmol       Date:  2016-10-18       Impact factor: 1.779

3.  Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy.

Authors:  Xing Wan; Han Pei; Min-jian Zhao; Shuo Yang; Wei-kun Hu; Heng He; Si-qi Ma; Ge Zhang; Xiao-yan Dong; Chen Chen; Dao-wen Wang; Bin Li
Journal:  Sci Rep       Date:  2016-02-19       Impact factor: 4.379

Review 4.  The Progress of Gene Therapy for Leber's Optic Hereditary Neuropathy.

Authors:  Yong Zhang; Zhen Tian; Jiajia Yuan; Chang Liu; Hong Li Liu; Si Qi Ma; Bin Li
Journal:  Curr Gene Ther       Date:  2017       Impact factor: 4.391

5.  Prognostic factors for visual acuity in patients with Leber's hereditary optic neuropathy after rAAV2-ND4 gene therapy.

Authors:  Yong Zhang; Xin Li; Jiajia Yuan; Zhen Tian; Hongli Liu; Dan Wang; Bin Li
Journal:  Clin Exp Ophthalmol       Date:  2019-05-08       Impact factor: 4.207

6.  Long-term outcomes of gene therapy for the treatment of Leber's hereditary optic neuropathy.

Authors:  Shuo Yang; Si-Qi Ma; Xing Wan; Heng He; Han Pei; Min-Jian Zhao; Chen Chen; Dao-Wen Wang; Xiao-Yan Dong; Jia-Jia Yuan; Bin Li
Journal:  EBioMedicine       Date:  2016-07-06       Impact factor: 8.143

7.  A retrospective analysis of characteristics of visual field damage in patients with Leber's hereditary optic neuropathy.

Authors:  Ruijin Ran; Shuo Yang; Heng He; Shiqi Ma; Zhiqi Chen; Bin Li
Journal:  Springerplus       Date:  2016-06-23

8.  Rapid high-resolution melting method to identify human leukocyte antigen-G (HLA-G) 3' untranslated region polymorphism +3142C/G (rs1063320).

Authors:  Hamza Ben Salah; Refka Jelassi; Ines Zidi; Amor Ben Amor; Sondes Bizid; Radhia Ammi; Lamia Guizani; Aida Bouratbine; Karim Aoun; Hanen Chelbi
Journal:  Mol Genet Genomic Med       Date:  2021-10-03       Impact factor: 2.183

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.